A Somatic Mutation Signature Predicts the Best Overall Response to Anti-programmed Cell Death Protein-1 Treatment in Epidermal Growth Factor Receptor/Anaplastic Lymphoma Kinase-Negative Non-squamous Non-small Cell Lung Cancer

BACKGROUND: We aimed to exploit a somatic mutation signature (SMS) to predict the best overall response to anti-programmed cell death protein-1 (PD-1) therapy in non-small cell lung cancer (NSCLC). METHODS: Tumor samples of 248 patients with epidermal growth factor receptor (EGFR)/anaplastic lymphom...

Descripción completa

Detalles Bibliográficos
Autores principales: Peng, Jie, Xiao, Lushan, Zou, Dan, Han, Lijie
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Medicine
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9112854/
https://www.ncbi.nlm.nih.gov/pubmed/35592856
http://dx.doi.org/10.3389/fmed.2022.808378

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9112854/
https://www.ncbi.nlm.nih.gov/pubmed/35592856
http://dx.doi.org/10.3389/fmed.2022.808378

Ejemplares similares